Why do we need observational studies of everyday patients in the real-life setting?

被引:103
作者
Cohen, Alexander T. [1 ]
Goto, Shinya [2 ]
Schreiber, Karen [1 ,3 ]
Torp-Pedersen, Christian [4 ]
机构
[1] Kings Coll London, Guys & St Thomas NHS Fdn Trust, Dept Haematol Med, London SE1 7EH, England
[2] Tokai Univ, Inst Med Sci, Hiratsuka, Kanagawa 25912, Japan
[3] Rigshosp, Copenhagen Univ Hosp, Dept Rheumatol, DK-2100 Copenhagen, Denmark
[4] Aalborg Univ, Aalborg, Denmark
关键词
Clinical trials; Real-life studies; Efficacy; Effectiveness; Safety; Special populations; Randomized controlled trials; ATRIAL-FIBRILLATION; ORAL ANTICOAGULANTS; VENOUS THROMBOEMBOLISM; RISK; PREVENTION; WARFARIN; STROKE; DABIGATRAN; REGISTRY; THERAPY;
D O I
10.1093/eurheartj/suv035
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Randomized controlled trials (RCTs) are performed with the primary goal of understanding the safety and efficacy of a new therapy in a selected group of patients. Even when evidence from these studies strongly favours a new therapy, its role in routine clinical practice may be unclear because of the considerable differences between its efficacy (in clinical trials) and its effectiveness (in the real-life setting). Real-life studies are observational studies that are essential to document benefits and harms of therapy in a wider population and to determine whether patients in routine practice are achieving expected outcomes. In the first article of this supplement, we discuss the relative strengths and limitations of RCTs and real-life studies and explore the current and potential uses of real-life studies in the field of thrombosis, including identifying new safety signals, assessing outcomes in special populations and raising questions about factors affecting medication adherence and persistence. Real-life studies provide a bridge from the results of RCTs to daily clinical practice.
引用
收藏
页码:D2 / D8
页数:7
相关论文
共 50 条
  • [21] DOAC plasma concentration upon hospital admission in a cohort of trauma patients. An observational real-life study
    Ruoff, Carolin
    Schoechl, Herbert
    Fritsch, Gerhard
    Voelckel, Wolfgang
    Zipperle, Johannes
    Gratz, Johannes
    Schmitt, Felix
    Oberladstaetter, Daniel
    EUROPEAN JOURNAL OF TRAUMA AND EMERGENCY SURGERY, 2023, 49 (06) : 2543 - 2551
  • [22] Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies
    Bassetti, Matteo
    Eckmann, Christian
    Bodmann, Klaus Friedrich
    Dupont, Herve
    Heizmann, Wolfgang R.
    Montravers, Philippe
    Guirao, Xavier
    Capparella, Maria Rita
    Simoneau, Damien
    Sanchez Garcia, Miguel
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 : ii5 - ii14
  • [23] Do we need more evidence for oral anticoagulants in everyday practice?
    Choi, Eue-Keun
    Lee, So-Ryoung
    HEART, 2021, 107 (12) : 943 - 944
  • [24] High rate of serious infection in juvenile idiopathic arthritis patients under biologic therapy in a real-life setting
    Brunelli, Juliana Barbosa
    Schmidt, Ana Renata
    Sallum, Adriana Maluf Elias
    Goldenstein-Schainberg, Claudia
    Bonfa, Eloisa
    Silva, Clovis A.
    Aikawa, Nadia Emi
    MODERN RHEUMATOLOGY, 2018, 28 (02) : 264 - 270
  • [25] 'Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review
    Abraham, I.
    Alhossan, A.
    Lee, C. S.
    Kutbi, H.
    MacDonald, K.
    ALLERGY, 2016, 71 (05) : 593 - 610
  • [26] Anticoagulation Duration After First Venous Thromboembolism: Real-Life Data From the International, Observational WHITE Study
    Palareti, Gualtiero
    Bignamini, Angelo A.
    Cini, Michela
    Li, Young-Jun
    Urbanek, Tomasz
    Madaric, Juraj
    Bouslama, Kamel
    Sokurenko, German Y.
    Andreozzi, Giuseppe M.
    Matugka, Jiri
    Mansilha, Armando
    Barinov, Victor
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2021, 27
  • [27] Benefit-risk assessment in a post-market setting: a case study integrating real-life experience into benefit-risk methodology
    Hallgreen, Christine E.
    van den Ham, Hendrika A.
    Mt-Isa, Shahrul
    Ashworth, Simon
    Hermann, Richard
    Hobbiger, Steve
    Luciani, Davide
    Micaleff, Alain
    Thomson, Andrew
    Wang, Nan
    van Staa, Tjeerd P.
    Downey, Gerald
    Hirsch, Ian
    Hockley, Kimberley
    Juhaeri, Juhaeri
    Metcalf, Marilyn
    Mwangi, Jeremiah
    Nixon, Richard
    Peters, Ruth
    Stoeckert, Isabelle
    Waddingham, Ed
    Tzoulaki, Ioanna
    Ashby, Deborah
    Wise, Lesley
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 (09) : 974 - 983
  • [28] Real-Life Peak and Trough Dabigatran Plasma Measurements Over Time in Hospitalized Geriatric Patients with Atrial Fibrillation
    Chaussade, E.
    Hanon, O.
    Boully, C.
    Labouree, F.
    Caillard, L.
    Gerotziafas, G.
    Vidal, J. -S.
    Elalamy, I.
    JOURNAL OF NUTRITION HEALTH & AGING, 2018, 22 (01) : 165 - 173
  • [29] What to expect after natalizumab cessation in a real-life setting
    Salhofer-Polanyi, S.
    Baumgartner, A.
    Kraus, J.
    Maida, E.
    Schmied, M.
    Leutmezer, F.
    ACTA NEUROLOGICA SCANDINAVICA, 2014, 130 (02): : 97 - 102
  • [30] Pazopanib for patients with advanced soft tissue sarcomas in a real-life setting
    Sleijfer, Stefan
    CANCER, 2016, 122 (09) : 1346 - 1348